Hawthorne S J, Pagano M, Halton D W, Walker B
Biomedicinal Chemistry Group, School of Pharmacy, Queen's University of Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland.
Biochem Biophys Res Commun. 2000 Oct 14;277(1):79-82. doi: 10.1006/bbrc.2000.3633.
A 30-kDa protease, purified previously from Fasciola hepatica, was sequenced and the first 15 N-terminal residues were found to be 100% homologous to a region in the protein Fcp1c, which was cloned and expressed from F. hepatica. This terminal region was also 53 and 54% identical to two other cathepsin L-like proteases isolated from the same source. The 30-kDa protease demonstrated a specificity different from humancathepsin L when assayed with novel peptidyl enediones of the type Z-Phe-Ala-CH&dbond;CH(2)-CO(2)R (where R = Me/Et/Bu(t)). The ethyl ester peptide was a more efficient inhibitor of the protease than the corresponding methyl ester. This is in contrast to bovine cathepsin B and human cathepsin L where both are more readily inhibited by the methyl, rather than the ethyl ester peptide. These differences in the inhibition of the novel parasite protease may allow it to be exploited as a chemotherapeutic target.
一种先前从肝片吸虫中纯化出的30 kDa蛋白酶经测序后发现,其N端的前15个残基与从肝片吸虫中克隆并表达的蛋白质Fcp1c中的一个区域100%同源。该末端区域与从同一来源分离出的另外两种组织蛋白酶L样蛋白酶的同源性也分别为53%和54%。在用新型肽基烯二酮Z-Phe-Ala-CH&dbond;CH(2)-CO(2)R(其中R = Me/Et/Bu(t))进行测定时,这种30 kDa蛋白酶表现出与人类组织蛋白酶L不同的特异性。乙酯肽对该蛋白酶的抑制作用比相应的甲酯更有效。这与牛组织蛋白酶B和人类组织蛋白酶L相反,它们更容易被甲酯肽而非乙酯肽抑制。新型寄生虫蛋白酶在抑制方面的这些差异可能使其成为一个可利用的化疗靶点。